Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

132.34 -1.83 (-1.37%)
Streaming Delayed Price Updated: 11:49 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Nvidia To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Abbott Laboratories (ABT) Q2 Earnings: What To Expect
Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results this Thursday morning. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Meta To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
3 Profitable Stocks to Research Further
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline. 
Via StockStory
Topics Economy Supply Chain
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ABT),(NASDAQ:DXCM),(NASDAQ:IRTC),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Abbott Laboratories Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
 
Via Benzinga
2 Dividend Stocks to Buy for Decades of Passive Income
Via The Motley Fool
Topics Intellectual Property
1 S&P 500 Stock to Research Further and 2 to Keep Off Your Radar
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
A proposal would cut Medicare reimbursements for some medical devices using a competitive bidding process. 
Via Investor's Business Daily
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Topics Artificial Intelligence
How Is The Market Feeling About Abbott Laboratories?
 
Via Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy
The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in. 
Via Benzinga
Thursday's session: top gainers and losers in the S&P500 index
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session. 
Via Chartmill
Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever
Forever is a tricky word in the stock market, but these stocks are as safe as they come and will pay you to hold them. 
Via The Motley Fool
Abbott, Dexcom Draw Retail Buzz As RFK Jr. Urges Americans To Embrace Health Wearables
Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom. 
Via Stocktwits
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q1 Earnings?
Abbott Laboratories has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 17.8% and now trades at $133.43. This performance may have investors... 
Via StockStory
Topics Stocks Supply Chain
ABBOTT LABORATORIES (NYSE:ABT) – A Quality Stock Worth Considering
ABBOTT LABORATORIES (NYSE:ABT) meets key quality investing criteria with strong revenue growth, high ROIC, and solid financial health, making it a stock worth considering for long-term portfolios. 
Via Chartmill
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Steady growth and dividend increases over decades can make investors remarkably wealthy. 
Via The Motley Fool
Topics Economy
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued
The agreement is to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with San Diego, California- based Tandem's innovative insulin... 
Via Stocktwits
3 Low-Volatility Stocks in Hot Water
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Peering Into Abbott Laboratories's Recent Short Interest
 
Via Benzinga
1 Mooning Stock with Exciting Potential and 2 to Think Twice About
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
ABBOTT LABORATORIES (NYSE:ABT) - A Strong Technical Setup for Breakout Investors
ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality setup, making it a potential breakout candidate for traders. 
Via Chartmill
3 Stocks With 3% to 9% Yields Just Raised Dividends Again
Via MarketBeat
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott
The company said the regulatory path forward for one of its key systems is too murky to pursue. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.